Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer. Perioperative durvalumab ...
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer. Perioperative durvalumab ...
Take a look through some of the notable data presentations at this year's ESMO Congress. Taking place October 23 to 27 in Madrid, Spain, the 2026 European Society for Medical Oncology (ESMO) Congress ...
The agency issued a PDUFA target action date of June 14, 2027. The FDA has accepted for review a new drug application (NDA) seeking approval of UGN-103 (mitomycin) for intravesical solution for ...
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years. Nogapendekin alfa inbakicept ...
Labeling would drop the limitation of use for age-related hypogonadism, reflecting an evidence reassessment that no longer supports language implying unestablished safety and effectiveness in this ...
Louise Emmett, MD, PhD, MBChB, FRACP, discusses findings from the phase 1 AcTION trial, which evaluated the safety and preliminary activity of 225Ac-PSMA-617 in patients with metastatic ...
A comprehensive guide to the practice-changing, paradigm-shifting studies across benign urologic conditions. At the 2026 Annual Meeting of the American Urological Association in Washington, DC, the P2 ...
A comprehensive guide to the practice-changing, paradigm-shifting studies across urologic oncology. Urologists will soon gather in Washington, DC, for the 2026 Annual Meeting of the American ...
FDA 510(k) clearance enables use of external neuromuscular stimulation to strengthen pelvic floor musculature and improve bladder control in men with post-prostatectomy incontinence. Daily home ...
The system can be used as an irrigation option for ureteroscopy, cystoscopy, percutaneous nephrolithotomy, and benign prostatic hyperplasia procedures. The FDA has granted 510(k) clearance to the ...
The ANDROMEDA trial compares alpha-emitting 225Ac-PSMA-617 and beta-emitting 177Lu-PSMA-617 with SBRT for recurrent oligometastatic prostate cancer. The trial builds on the LUNAR trial, which showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results